GlobeNewswire, Sixty Levels Prescription drugs, 12.26.2023, experiences on “60 Levels Pharma Proclaims IRB Approval of Section IIA Examine to Consider Tafenoquine for Babesiosis, an Rising Tick-Borne Illness; Sort C Assembly Re-Scheduled by FDA to January 17, 2024.” This text from 60 Levels Prescription drugs, Inc. highlights a number of key updates and developments concerning their investigational drug, tafenoquine, for the therapy of babesiosis, an rising tick-borne illness. Babesiosis is a probably life-threatening tick-borne sickness on the rise in the USA, estimated to have an effect on round 47,000 people yearly. It’s usually present in areas the place Lyme disease is prevalent and will be transmitted by means of tick bites or contaminated blood transfusions.
60 Levels Prescription drugs acquired approval from an Investigational Assessment Board (IRB) to conduct a Section IIA scientific research. This research goals to guage the security and effectiveness of tafenoquine together with commonplace care medicines for hospitalized babesiosis sufferers. Tafenoquine is at present authorized as ARAKODA® for malaria prophylaxis. Its lengthy half-life suggests potential benefits in less-frequent dosing for malaria prevention.
The upcoming assembly presumably entails discussions concerning the growth and potential approval of tafenoquine for treating babesiosis. The press launch outlines essential security info concerning using ARAKODA® for malaria prophylaxis, indicating contraindications, warnings, precautions, and antagonistic reactions.
For Extra Data:
Read the full article on GlobeNewswire’s website here.
Read LDA’s Post: Relapsing Babesiosis Case Treated Successfully with Tafenoquine
Read LDA’s Post: Tafenoquine as Treatment for Relapsing Babesiosis
The publish IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis appeared first on Lyme Disease Association.
